Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019)
Perkovic, V; Jardine, M. J; Neal, B; Bompoint, S; Heerspink, H. J. L; Charytan, D. M; Edwards, R; Agarwal, R; Bakris, G; Noronha, Irene de Lourdes 
Source: New england journal of medicine. Unidade: FM
Subjects: CREATINA, DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FALÊNCIA RENAL CRÔNICA, GLICOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PERKOVIC, V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New england journal of medicine, v. 380, n. 24, p. 2295-2306, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1811744. Acesso em: 03 maio 2024.APA
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New england journal of medicine, 380( 24), 2295-2306. doi:10.1056/NEJMoa1811744NLM
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Noronha I de L. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [Internet]. New england journal of medicine. 2019 ; 380( 24): 2295-2306.[citado 2024 maio 03 ] Available from: https://doi.org/10.1056/NEJMoa1811744Vancouver
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Noronha I de L. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [Internet]. New england journal of medicine. 2019 ; 380( 24): 2295-2306.[citado 2024 maio 03 ] Available from: https://doi.org/10.1056/NEJMoa1811744
